Patent Yard Sign in
Canadian application, no grantCanada

Assaying apparatus, kit, and method for lipids and associated enzymes

CA 2676478 A1 · Owner: Echelon Biosciences Inc. · Inventors: Prestwich, Glenn; Mostert, Michael J.; Neilsen, Paul O.

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

A lipid assay method, kit, and apparatus involving exposure of a protein, having a lipid recognition motif that interacts with a target lipid and a , competing lipid, to a solution containing the competing lipid and determining , whether the target lipid is present in the solution. The target lipid has a stronger , affinity to the lipid recognition motif than does the competing lipid. The lipid , recognition motif is preferably a pleckstrin homology (PH) domain with the , target , lipid being a phosphoinositide. The assay determines activity of a lipid kinase, the , target lipid being a phosphorylation product of a reaction between the lipid kinase , and a substrate lipid. The assay …

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed November 20, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 20, 2022.
  • A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 20, 2024.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledNovember 20, 2002
GrantedNo grant recorded
Term endedNovember 20, 2022
Patent numberCA 2676478 A1
Classification (IPC)G01N33/57 +2 more

Timeline

Timeline From CIPO dates

2003200520072009201120132015201720192021Application filedNov 20, 2002Term endedNov 20, 2022

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.